Karuna Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KRTX research report →
Range $150 – $330
Price Chart
About the company
Operating as a clinical-stage biopharmaceutical firm, Karuna Therapeutics, Inc. is dedicated to pioneering innovative therapies for individuals afflicted by psychiatric and neurological disorders. Its primary investigational compound, KarXT, is an oral agent designed to modulate muscarinic receptors.
- CEO
- William Meury
- IPO
- 2019
- Employees
- 339
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on KRTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $12.60B
- P/E
- -28.12
- Fwd P/E
- 663.31
- PEG
- 1.02
- P/S
- 19264.95
- P/B
- 9.72
- EV/EBITDA
- -25.21
- Div Yield
- 0.00%
- Gross Margin
- -160.09%
- Op Margin
- -75653.98%
- Net Margin
- -66311.93%
- ROE
- -36.44%
- ROIC
- -38.93%
Latest fiscal year · YoY change
- Revenue
- $654.00K-93.9%
- Gross Profit
- $-1,047,000-111.0%
- Op Income
- $-494,777,000
- Net Income
- $-433,680,000-56.9%
- EPS
- $-11.73-34.2%
- OCF Growth
- -69.2%
- FCF Growth
- -69.8%
- 52W High
- $329.99
- 52W Low
- $158.38
- 50D MA
- $317.38
- 200D MA
- $228.31
- Beta
- 1.15
- RSI (14)
- 75
- Avg Volume
- 971.83K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Karuna said KarXT’s NDA submission is complete, the launch plan remains on track, and the company ended Q3 with $1.3 billion in cash to fund operations comfortably through 2026.· November 2, 2023
- KarXT NDA was submitted; management expects FDA filing acceptance later this month and a potential approval/launch in the second half of 2024.
- Q3 operating expenses were $136.2 million, with R&D at $104 million and G&A at $32.3 million; net loss was $119.1 million.
- Cash, cash equivalents and investments were $1.3 billion at Sept. 30, 2023, up from $1.1 billion at year-end 2022, and the company said runway extends comfortably through 2026.
- Pre-commercial work is underway, including payer scientific exchange, sales force planning, and sampling prep; management said launch readiness is ahead of schedule.
- Pipeline work continues in ARISE, ADEPT, and KAR-2618, with additional data readouts expected over the next several quarters.
Karuna reported third-quarter 2023 total operating expenses of $136.2 million versus $81.1 million a year ago. R&D expense was $104 million versus $62 million last year, and G&A was $32.3 million versus $19.1 million last year. Interest income was $17 million, resulting in a net loss of $119.1 million. Cash, cash equivalents and investment securities totaled $1.3 billion as of Sept. 30, 2023, compared with $1.1 billion at the end of 2022, and management said that supports a runway comfortably through 2026. For full-year 2023, Karuna reiterated guidance for total operating expenses toward the top end of the range at about $470 million, with R&D at $355 million and G&A at $115 million.
Bill Meury framed the quarter around the NDA submission for KarXT as a major company milestone after years of development work, calling it the first step in the regulatory review process. He emphasized that prelaunch work, payer engagement, and commercial planning are on track, and he repeatedly described KarXT as a potentially important launch for schizophrenia because it would represent a novel mechanism after decades of one dominant class of treatment. He also highlighted momentum in the broader pipeline, including ARISE, ADEPT, and KAR-2618, and said the company has the funding and capabilities to execute its plans.
Jason Brown said Q3 was strong operationally, with spending driven by ongoing Phase 3 work, the NDA submission, and pre-commercialization activities. He quantified R&D at $104 million and G&A at $32.3 million, both above the prior-year period due to clinical program activity, higher headcount, stock-based compensation, and launch preparation. He reiterated full-year 2023 operating expense guidance of about $470 million, with R&D at $355 million and G&A at $115 million, and noted the $1.3 billion cash balance provides runway through 2026.
Analysts focused heavily on the ABPM blood-pressure study, and management said they are highly confident it will not trigger a major amendment or extend the PDUFA review timeline, pointing to prior FDA discussion and the lack of a meaningful blood-pressure signal in the broader program so far. Questions also centered on ARISE enrollment, AD psychosis versus agitation, payer feedback, and the commercial launch plan; management said ARISE is seeing ongoing site activation, payer discussions have been positive, and the launch will be broad-based with strong emphasis on Medicaid coverage. On KAR-2618, management said MDD is the initial focus because of the preclinical rationale and existing human safety experience, while anxiety disorders remain of interest.
The company believes KarXT’s differentiated mechanism and tolerability profile could support a major launch in schizophrenia, and management said payer and clinician interest is already high. Financially, the balance sheet is strong with $1.3 billion in cash and a runway comfortably through 2026, giving Karuna time to execute across approval, launch prep, and pipeline development.
A lot still has to go right: the NDA is only at the filing stage, FDA acceptance and later review milestones are still ahead, and the company acknowledged the potential for an ABPM data point even if it expects no major issue. Pipeline programs such as ARISE and ADEPT are still enrolling and depend on finding the right patients and maintaining site momentum, while KAR-2618 remains early and still needs human efficacy data.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.9%
- Shares Outstanding
- 38.20M
- Float Shares
- 36.27M
of shares held by institutions
363 13F filers
Buy/sell ratio 0.17. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for KRTX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Daniel GoldmanHouse · NY10 | Sell | Apr 10, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Pictet Asset Management SA | 213.48K | ▼ 31.84K |
| Tekla Capital Management LLC | 58.58K | ▲ 5.13K |
| International Biotechnology Trust PLC | 30.50K | ▲ 4.80K |
| Ea Series Trust | 12.84K | ▲ 12.84K |
| Kellner Capital, LLC | 4.10K | ▲ 4.10K |
| Weiss Multi-Strategy Advisers LLC | 1.00K | ▼ 9.00K |
Held by 2 ETFs
Biggest fund positions in KRTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 24 | Wheadon David E. | sell | 25,000 |
| Mar 18, 24 | Wheadon David E. | sell | 8,500 |
| Mar 18, 24 | Wheadon David E. | sell | 990 |
| Mar 18, 24 | Wheadon David E. | sell | 5,000 |
| Mar 18, 24 | Wheadon David E. | sell | 1,904 |
| Mar 18, 24 | Torres Denice | sell | 990 |
| Mar 18, 24 | Torres Denice | sell | 5,000 |
| Mar 18, 24 | Torres Denice | sell | 1,904 |
| Mar 18, 24 | Torres Denice | sell | 8,500 |
| Mar 18, 24 | Torres Denice | sell | 25,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KRTX coverage
Recent articles, reports, and earnings notes.
No research on KRTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KRTX report →Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout
zacks.com · Feb 23
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
businesswire.com · Feb 22
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX
businesswire.com · Feb 14
Bullish Continuation in '24? 3 Market Areas to Watch
zacks.com · Jan 10
Cramer names biopharma companies to watch as industry mergers start to pile up
cnbc.com · Jan 5
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX
businesswire.com · Dec 31
Yes Virginia, There Is a Santa Claus Rally
zacks.com · Dec 26
Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers
zacks.com · Dec 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.